Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections

被引:9
作者
Wenzler, S [1 ]
Schmidt-Eisenlohr, E [1 ]
Daschner, F [1 ]
机构
[1] Univ Hosp Freiburg, Inst Environm Med & Hosp Epidemiol, D-79106 Freiburg, Germany
关键词
gatifloxacin; moxifloxacin; quinolone; respiratory tract infection; wound infection;
D O I
10.1159/000077284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In our study the in vitro susceptibility of common pathogens that cause respiratory tract and abdominal wound infections was tested against two newer fluorquinolones (moxifloxacin and gatifloxacin) as well as levofloxacin and azithromycin. Methods: 50 isolates each of methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Pseudomonas aeruginosa and Haemophilus influenzae isolated from the respiratory tract and from wounds were tested for their susceptibility to moxifloxacin, gatifloxacin, levofloxacin and azithromycin. Results: Moxifloxacin proved to be the most active substance against the tested gram-positive pathogens. Gatifloxacin was the most active against P. aeruginosa. Moxifloxacin and gatifloxacin proved to be comparably active against the clinical isolates of E. coli and H. influenzae. Conclusions: Moxifloxacin and gatifloxacin display excellent activity against respiratory pathogens as well as nosocomial pathogens causing abdominal wound infections. When treating infections caused by P. aeruginosa the earlier fluorquinolones such as ciprofloxacin or ofloxacin are the substances of choice. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:40 / 42
页数:3
相关论文
共 6 条
[1]   Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria [J].
Ackermann, G ;
Schaumann, R ;
Pless, B ;
Claros, MC ;
Goldstein, EJC ;
Rodloff, AC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (03) :228-232
[2]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[3]   In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program [J].
Jones, RN ;
Pfaller, MA .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S16-S23
[4]   Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test [J].
Madhusudhan, KT ;
Counts, C ;
Lody, C ;
Carter, O ;
Dodson, S ;
Ojha, N .
CHEMOTHERAPY, 2003, 49 (04) :184-188
[5]   Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae [J].
Saravolatz, L ;
Manzor, O ;
Check, C ;
Pawlak, J ;
Belian, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (06) :875-877
[6]   In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media [J].
Yagupsky, P ;
Katz, O ;
Peled, N ;
Dagan, R .
CHEMOTHERAPY, 2001, 47 (05) :354-358